Effect of Amino Acids and Sugar Alcohols on Satiation Peptides and Activation of Specific Brain Regions
Not Applicable
Completed
- Conditions
- Endocrine System Diseases
- Interventions
- Dietary Supplement: 1.56 g L-LeucineDietary Supplement: 50 g XylitolDietary Supplement: 1.56 g L-TryptophanDietary Supplement: 75 g ErythritolDietary Supplement: 75 g GlucoseDietary Supplement: Tap waterDietary Supplement: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)Device: Nasogastric Tube
- Registration Number
- NCT02823249
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
With this study the investigators investigate the effects of amino acids (tryptophan, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms and brain activation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Healthy normal weight subjects with a body-mass index of 19.0-24.9
- Healthy obese subjects with a body-mass index of > 30
- Normal eating habits (no diets; no dietary changes; no special dietary habits such as vegetarian/vegan)
- Age 18-40 years
- Stable body weight for at least three months
Exclusion Criteria
- Smoking
- Substance abuse
- Regular intake of medications (except for oral contraceptives)
- Medical or psychiatric illness
- History of gastrointestinal disorders
- Food allergies
- Pregnancy, breast feeding
- Body piercings that cannot be removed
- History of claustrophobia
- Left-hander
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1.56 g L-Tryptophan Tap water 1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Leucine 1.56 g L-Leucine 1.56 g L-Leucine in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 75 g Erythritol Tap water 75 g Erythritol in 300 mL tap water given via nasogastric tube 50 g Xylitol 50 g Xylitol 50 g Xylitol in 300 mL tap water given via nasogastric tube 75 g Glucose and mixed liquid meal Tap water 75 g Glucose in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Tryptophan 1.56 g L-Tryptophan 1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Tryptophan Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) 1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Tryptophan Nasogastric Tube 1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 75 g Erythritol 75 g Erythritol 75 g Erythritol in 300 mL tap water given via nasogastric tube 75 g Glucose and mixed liquid meal 75 g Glucose 75 g Glucose in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Leucine Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) 1.56 g L-Leucine in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 50 g Xylitol Tap water 50 g Xylitol in 300 mL tap water given via nasogastric tube 50 g Xylitol Nasogastric Tube 50 g Xylitol in 300 mL tap water given via nasogastric tube 75 g Glucose and mixed liquid meal Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) 75 g Glucose in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube Tap water and mixed liquid meal Tap water 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Leucine Tap water 1.56 g L-Leucine in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 1.56 g L-Leucine Nasogastric Tube 1.56 g L-Leucine in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube 75 g Erythritol Nasogastric Tube 75 g Erythritol in 300 mL tap water given via nasogastric tube 75 g Glucose and mixed liquid meal Nasogastric Tube 75 g Glucose in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube Tap water and mixed liquid meal Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube Tap water and mixed liquid meal Nasogastric Tube 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
- Primary Outcome Measures
Name Time Method Effect of sugar alcohols on cerebral blood flow measured by functional brain MRI changes from baseline to one hour after treatment Effect of aminoacids on cerebral blood flow measured by functional brain MRI changes from baseline to one hour after treatment
- Secondary Outcome Measures
Name Time Method Measurement of Plasma cholecystokinin concentrations changes from baseline to three hours after treatment Measurement of Plasma Glucagon-like Peptide (GLP-1) concentrations changes from baseline to three hours after treatment Measurement of Plasma PYY concentrations changes from baseline to three hours after treatment Measurement of Plasma ghrelin concentrations changes from baseline to three hours after treatment Measurement of Plasma Glucose concentrations changes from baseline to three hours after treatment Measurement of Plasma Insulin concentrations changes from baseline to three hours after treatment
Trial Locations
- Locations (1)
University Hospital Basel
🇨🇭Basel, Basel-Stadt, Switzerland